Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
about
Trial WatchTrial Watch: Adoptive cell transfer for oncological indicationsThe Yin and Yang of Toll-like receptors in cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial watch: IDO inhibitors in cancer therapyTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyTrial watch: Cardiac glycosides and cancer therapyTherapeutic cancer vaccines and combination immunotherapies involving vaccinationCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growthTrial Watch: Toll-like receptor agonists in oncological indications.Trial watch: Immunostimulatory cytokines in cancer therapy.Toll-like receptors and ischemic brain injury.Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsReprogramming the response to stroke by preconditioningSerum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerThe efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40Classification of current anticancer immunotherapiesExpression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated responseTargeting the tumor microenvironment to enhance antitumor immune responsesThree steps to breaking immune tolerance to lymphoma: a microparticle approach.4T1 Murine Mammary Carcinoma Cells Enhance Macrophage-Mediated Innate Inflammatory Responses.Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaTargeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell LinesTrial watch: Dendritic cell-based interventions for cancer therapyTrial watch: Prognostic and predictive value of the immune infiltrate in cancerTrial watch: Peptide vaccines in cancer therapyImmunotherapy in pediatric malignancies: current status and future perspectivesCellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4.Trial watch: DNA vaccines for cancer therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Trial watch: Oncolytic viruses for cancer therapyImmunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
P2860
Q24618653-5B9E0E94-4CE5-4E37-91CD-93786950B396Q26785545-50DCC17D-3823-4200-AFB8-BAF5C35DD73DQ26851526-E8CBDD18-555A-4D39-B01C-155662890E44Q26993238-45AF20FE-6DC3-4827-BCFC-600BA67F103DQ27006866-70566683-63AA-431F-A397-6A9B91B80CD5Q27021951-41721F40-ED0A-4A71-8923-7CA2B717112CQ28067939-71F47916-B309-4E93-ADAA-E3976EEBF441Q28395830-44F98EF6-D7BC-4FC0-913E-9924FBE2042AQ28397609-42D862F3-59D9-4A9A-8301-27F8DF8D3901Q30358185-39D3E373-065C-4104-AF8B-D1996953EDFCQ30842176-830F577A-771D-422D-A693-D5DF4EDC97F2Q33878578-8F0BA6EF-247B-4CCF-9116-5FB9A8F3401BQ33880165-B180B6E8-43EF-46DF-970D-09114DFA537EQ33972758-A8B4C6C8-4F9B-4597-9E26-18E3FE3D04ECQ33978723-541BD1D8-AA06-400D-9E02-43FD36E1FBB5Q34011491-834CD867-4040-4B44-A288-F3B45B43EDA4Q34555863-38D9E00A-C6F1-4E0E-AA7B-5D2A8BF2BB1BQ34733049-3AB2CFC3-067B-404D-AC56-103A703A8B3AQ34859794-8E5BDC28-C854-4FF2-B599-4EC8CBBDA00AQ34993170-BE6F715B-09B1-44E0-8727-7D3245855777Q35040383-76BF4CDD-E1D9-47F8-B9EB-C2512CBEC74CQ35060384-1A18890F-8197-48DF-AA4E-B3CAB1DB3403Q35149637-35A4101F-BDFF-43F9-A31D-F1A0A5ADCA69Q35164128-57C744B1-93E5-4A16-94EF-5C3A9E8D6098Q35176307-9B8B0BD2-1963-4B72-B619-B13AF6A77E95Q35328686-0114A0FE-0469-44F0-A200-E56AFD79A725Q35692431-B061F7D8-A4E0-4D57-A769-F9BE991C70AFQ35799377-D1D02D7C-E39D-4502-9F9C-20BE356D3D81Q35833184-40287427-BFD9-4970-890F-34004C9B9274Q36218717-3C70F08E-81AB-4A8B-9034-E824DD594652Q36388529-53800933-F274-46DA-96A1-219E7B5E2324Q36456483-206A9517-26FD-4BF9-8964-D59A3BC54FDCQ36476100-F3EACE4F-C229-4425-B010-EA22134EC689Q36691818-7EAF0435-103C-4300-BC05-3673C4EC352CQ36810015-5DBBCC11-BCF7-43C8-ADDE-F143B8493336Q36845824-939AF560-DD6B-4AE0-A92E-162CD26E63E8Q36887833-FFC2695C-80AB-4249-A485-561649D37FDDQ37028023-7DDCE17B-6B45-43A4-967B-55CDA2ED1E4EQ37379408-A674A275-2A18-42C9-851E-43CFDEA906A9Q37652790-01DF7B0D-DD81-4C6D-9856-68FE374DAFCB
P2860
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@ast
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@en
type
label
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@ast
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@en
prefLabel
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@ast
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@en
P2860
P50
P356
P1433
P1476
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
@en
P2860
P304
P356
10.4161/ONCI.20931
P50
P577
2012-09-01T00:00:00Z